Clinical Trial Update: A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating vadastuximab talirine administered before or after allogeneic stem cell transplant in acute myeloid leukemia; study terminated with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Vadastuximab Talirine (Vadastuximab Talirine)

Snippet

Sponsor: Seagen Inc. | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-01-09